Description: Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.
Home Page: www.ryvu.com
Leona Henryka Sternbacha 2
Kraków,
30-394
Poland
Phone:
48 12 314 0200
Officers
| Name | Title |
|---|---|
| Mr. Pawel Tadeusz Przewiezlikowski M.B.A., M.Sc. | Founder, Pres of the Management Board & CEO |
| Dr. Krzysztof Daniel Brzózka M.B.A., Ph.D. | Exec. VP, Chief Scientific Officer & VP of the Management Board |
| Mr. Dawid Patryk Radziszewski | Member of the Management Board |
| Mr. Dariusz Tomasz Kurdas | Member of the Management Board |
| Dr. Kamil Sitarz M.B.A., Ph.D. | Chief Operating Officer |
| Mr. Vatnak Vat-Ho M.B.A. | Member of Management Board |
| Dr. Hendrik Nogai M.D. | Member of Management Board |
| Dr. Adrijana Vinter | Member of Management Board |
| Mr. Tomasz Nocun | Director of Investments & Devel. |
| Ms. Paulina Wolanin | HR Mang. |
Exchange: WAR
Country: PL
Currency: Polish złoty (zł)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.2659 |
| Price-to-Sales TTM: | 25.4427 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 199 |